This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Solorzano, C. C. Articles by Ellis, L. M. Search for Related Content PubMed PubMed Citation Articles by Solorzano, C. C. Articles by Ellis, L. M.

In Vivo Intracellular Signaling as a Marker of Antiangiogenic Activity¹

Departments of Surgical Oncology [C. C. S., L. M. E.] and Cancer Biology [Y. D. J., C. D. B., D. J. M., G. E. G., L. M. E.], University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, and SUGEN, Inc., South San Francisco, California 94080 [G. M.]

Alterations in endothelial cell (EC) signaling could serve as a marker of effective antiangiogenic therapy. We determined the effect of an antiangiogenic tyrosine kinase inhibitor, SU6668, on tumor EC signaling in liver metastases in mice. In vitro immunofluorescence verified that pretreatment of ECs with SU6668 before exposure to VEGF decreased in vitro phosphorylation of Erk and Akt. Using double-fluorescence immunohistochemistry, phosphorylated Erk and Akt were constitutively expressed in ECs in liver metastases in untreated mice, but SU6668 blocked activation of these signaling intermediates. Determining the activation status of the Erk and Akt signaling pathways in tumor ECs may serve as a surrogate marker for the effectiveness of antiangiogenic regimens.

This article has been cited by other articles:

				W. Wen, J. Lu, K. Zhang, and S. Chen Grape Seed Extract Inhibits Angiogenesis via Suppression of the Vascular Endothelial Growth Factor Receptor Signaling Pathway Cancer Prevention Research, December 1, 2008; 1(7): 554 - 561. [Abstract] [Full Text] [PDF]

				E. Naumova, P. Ubezio, A. Garofalo, P. Borsotti, L. Cassis, E. Riccardi, E. Scanziani, S. A. Eccles, M. R. Bani, and R. Giavazzi The Vascular Targeting Property of Paclitaxel Is Enhanced by SU6668, a Receptor Tyrosine Kinase Inhibitor, Causing Apoptosis of Endothelial Cells and Inhibition of Angiogenesis. Clin. Cancer Res., March 15, 2006; 12(6): 1839 - 1849. [Abstract] [Full Text] [PDF]

				S. Sengupta, L. A. Sellers, R.-C. Li, E. Gherardi, G. Zhao, N. Watson, R. Sasisekharan, and T.-P. D. Fan Targeting of Mitogen-Activated Protein Kinases and Phosphatidylinositol 3 Kinase Inhibits Hepatocyte Growth Factor/Scatter Factor-Induced Angiogenesis Circulation, June 17, 2003; 107(23): 2955 - 2961. [Abstract] [Full Text] [PDF]

				N. Reinmuth, W. Liu, F. Fan, Y. D. Jung, S. A. Ahmad, O. Stoeltzing, C. D. Bucana, R. Radinsky, and L. M. Ellis Blockade of Insulin-like Growth Factor I Receptor Function Inhibits Growth and Angiogenesis of Colon Cancer Clin. Cancer Res., October 1, 2002; 8(10): 3259 - 3269. [Abstract] [Full Text] [PDF]

				R. J. Bernardi, C. S. Johnson, R. A. Modzelewski, and D. L. Trump Antiproliferative Effects of 1{alpha},25-Dihydroxyvitamin D3 and Vitamin D Analogs on Tumor-Derived Endothelial Cells Endocrinology, July 1, 2002; 143(7): 2508 - 2514. [Abstract] [Full Text] [PDF]